drugset / Trial / NCT05324774
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase III clinical study of the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in patients with diabetic macular edema (DME) in a multicenter, randomized, double-blind, parallel active-controlled study.
Timeline
- Start
- 2022-02-28
- Primary completion
- 2023-09-30
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW0813 | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |